Please assess the completion status of the following clinical trial:

Trial Title: Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Blunt trauma~* Pre-hospital Glasgow Coma Scale equal to or less than 8(GCS≤8)\*~* Age 15 years or older or 50 kg or more~  * Patients who met the inclusion criteria above and did not meet the exclusion criteria below but who had systolic blood pressure (SBP) ≤70 or SBP\>70 and SBP≤90 and heart rate (HR)≥108 were included in the Hypertonic Resuscitation following Traumatic Injury study that focused on shock patients who may or may not have a traumatic brain injury (TBI). In other words, patients with both TBI and shock would not be included in this study of TBI patients without shock at the time of enrollment.~Exclusion Criteria:~* Known or suspected pregnancy~* Age younger than 15 years or less than 50 kg if age unknown~* Ongoing pre-hospital cardiopulmonary resuscitation (CPR)~* Administration of more than 2L crystalloid or any colloid or blood products~* Severe hypothermia (T less than 28C)~* Drowning or asphyxia due to hanging~* Burns TBSA more than 20%~* Isolated penetrating injury to the head~* Inability to obtain pre-hospital intravenous access~* Time of call received at dispatch to study intervention more than four hours~* Known prisoners

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 7.5% hypertonic saline/6% dextran (HSD) (Type: EXPERIMENTAL): 250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
- 7.5% hypertonic saline (HS) (Type: EXPERIMENTAL): 250 ml intravenous bolus administration of 7.5% hypertonic saline
- 0.9% normal saline (NS) (Type: PLACEBO_COMPARATOR): 250 ml intravenous bolus administration of 0.9% saline

Based on this trial design, predict the completion outcome and termination type (if applicable).